Terrica Inc (TRCA1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
651 GATEWAY BLVD SUITE 950 SOUTH SAN FRANCISCO, CA 94060

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Focuses on the development and commercialization of new therapeutics for the treatment of short stature and other related metabolic disorders. The company is in the development stage (June 30, 2005); its product candidate is Increlex, a DNA-derived recombinant human insulin-like growth factor-1.

View SEC Filings from TRCA1 instead.

View recent insider trading info

Funds Holding TRCA1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TRCA1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MORRISON DALE F

0 2021-03-03 0

PILNICK GARY H

0 2021-03-03 0

TWIN RIDGE CAPITAL SPONSOR, LLC

0 2021-03-03 0

BURNS ALISON SARAH

0 2021-03-03 0

MOREY SANJAY KRISHNAKUMAR CO-CEO AND PRESIDENT

0 2021-03-03 0

RUSSELL WILLIAM PETER JR CO-CEO AND CFO

0 2021-03-03 0

HENRYS PAUL

0 2021-03-03 0

KING RICHARD PRESIDENT AND C.O.O.

  • Officer
No longer subject to file 2008-10-16 0

LESCHLY MARK

  • Director
No longer subject to file 2008-10-16 0

BARKAS ALEXANDER E

  • Director
No longer subject to file 2008-10-16 0

MAHONEY DAVID L

  • Director
No longer subject to file 2008-10-16 0

EASTHAM KARIN

  • Director
No longer subject to file 2008-10-16 0

BANSAL AJAY CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2008-10-16 0

ROSENFIELD STEPHEN EXECUTIVE VP OF LEGAL AFFAIRS

  • Officer
No longer subject to file 2008-10-16 0

GRETHLEIN ANDREW J SVP, PHARMACETICAL OPERATIONS

  • Officer
No longer subject to file 2008-10-16 0

SCARLETT JOHN A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2008-10-16 0

WONG SUSAN VP FINANCE & CHIEF ACCTG OFFCR

  • Officer
No longer subject to file 2008-10-16 0

VON STEIN THORSTEN SVP AND CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2008-10-16 0

HASNAIN FAHEEM

  • Director
No longer subject to file 2008-10-16 0

JEAN CHRISTOPHE

  • Director
No longer subject to file 2008-10-16 0

IPSEN, S.A.

  • 10% Owner
21,451,870 2007-07-30 0

BELINGARD JEAN LUC

  • Director
11,250 2007-05-24 0

HENNER DENNIS

  • Director
  • 10% Owner
11,250 2007-05-24 0

IPSEN, S.A.

SURAYPHARM, SAS

  • 10% Owner
57,518,572 2006-10-13 0

WIGGANS THOMAS G

  • Director
11,250 2006-06-06 0

ASTRUE MICHAEL J

  • Director
11,250 2006-06-06 0

CLARK ROSS G CHIEF TECHNICAL OFFICER

  • Officer
  • Director
66,337 2006-04-21 0

RIVERA CHRISTOPHER EUGENE SNR VP, COMMERCIAL OPERATIONS

  • Officer
65,000 2006-03-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments